Research Article
Open Access
Disrupted in renal carcinoma 2 (DIRC2/SLC49A4) is an H+-driven lysosomal pyridoxine exporter
View ORCID ProfileShogo Akino, View ORCID ProfileTomoya Yasujima Correspondence email, Takahiro Yamashiro, Hiroaki Yuasa
Shogo Akino
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
Roles: Formal analysis, Investigation, Visualization, Methodology
Tomoya Yasujima
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
Roles: Conceptualization, Formal analysis, Funding acquisition, Investigation, Visualization, Methodology, Writing—original draft
Takahiro Yamashiro
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
Roles: Investigation, Methodology
Hiroaki Yuasa
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University, Nagoya, Japan
Roles: Conceptualization, Supervision, Project administration, Writing—review and editing
Published 1 December 2022. DOI: 10.26508/lsa.202201629
Statistics from Altmetric.com
Article usage
DIRC2 is an H+-driven lysosomal pyridoxine exporter
Shogo Akino, Tomoya Yasujima, Takahiro Yamashiro, Hiroaki Yuasa
Life Science Alliance Dec 2022, 6 (2) e202201629; DOI: 10.26508/lsa.202201629
In this Issue
Volume 6, No. 2
February 2023
Advertisement
Jump to section
Subjects
Related Articles
- No related articles found.